Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prednisolone + prednisone is a combination of two synthetic glucocorticoid corticosteroids, both of which are used for their anti-inflammatory and immunosuppressive properties. Prednisone is a prodrug that must be converted in the liver to its active form, prednisolone. Both drugs act by binding to the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory effects. They are commonly prescribed for a wide range of conditions including autoimmune diseases (such as rheumatoid arthritis and lupus), severe allergies, asthma, skin disorders, certain cancers (like leukemia), inflammatory bowel disease, and adrenal insufficiency[1][3][5][6][7]. The combination itself is not standard clinical practice since both drugs have overlapping mechanisms; typically one or the other is prescribed based on patient-specific factors such as liver function[7]. However, if administered together (for example during transitions or special clinical circumstances), their combined effect would be additive in terms of glucocorticoid activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prednisolone + prednisone.